{"product_id":"computational-pharmaceutical-solid-state-chemistry-9781118700747","title":"Computational Pharmaceutical Solid State","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book is the first to combine computational material science and modeling of molecular solid states for pharmaceutical industry applications.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors xiii\u003c\/p\u003e \u003cp\u003ePreface xvii\u003c\/p\u003e \u003cp\u003eEditor’s biography xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Computational Pharmaceutical Solid‐State Chemistry: An Introduction 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eYuriy A. Abramov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Pharmaceutical Solid‐State Landscape 2\u003c\/p\u003e \u003cp\u003e1.2.1 Some Definitions 2\u003c\/p\u003e \u003cp\u003e1.2.2 Impact of Solid‐State Form on API and Product Properties 4\u003c\/p\u003e \u003cp\u003e1.2.3 Challenges of Pharmaceutical Industry Related to Solid Form Selection 6\u003c\/p\u003e \u003cp\u003e1.3 Pharmaceutical Computational Solid‐State Chemistry 8\u003c\/p\u003e \u003cp\u003e1.4 Conclusions 9\u003c\/p\u003e \u003cp\u003eAcknowledgment 10\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Navigating the Solid Form Landscape with Structural Informatics 15\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePeter T. A. Galek, Elna Pidcock, Peter A. Wood, Neil Feeder, and Frank H. Allen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 15\u003c\/p\u003e \u003cp\u003e2.2 The CSD System 17\u003c\/p\u003e \u003cp\u003e2.3 Hydrogen‐Bond Propensity: Theory and Applications to Polymorphism 18\u003c\/p\u003e \u003cp\u003e2.3.1 Methodology 18\u003c\/p\u003e \u003cp\u003e2.3.2 Case Study 1: Ritonavir 19\u003c\/p\u003e \u003cp\u003e2.4 Hydrogen‐Bond Landscapes: Developing the Propensity Approach 21\u003c\/p\u003e \u003cp\u003e2.4.1 Methodology 21\u003c\/p\u003e \u003cp\u003e2.4.2 Case Study 2: Metastable versus Stable Form of Piroxicam 22\u003c\/p\u003e \u003cp\u003e2.4.3 Case Study 3: Exploring the Likely Hydrogen‐Bond Landscape of Axitinib (Inlyta®) 25\u003c\/p\u003e \u003cp\u003e2.5 Informatics‐Based Cocrystal Screening 25\u003c\/p\u003e \u003cp\u003e2.5.1 Methodology 25\u003c\/p\u003e \u003cp\u003e2.5.2 Case Study 4: Paracetamol 26\u003c\/p\u003e \u003cp\u003e2.5.3 Case Study 5: AMG 517 – Sorbic Acid Cocrystal 29\u003c\/p\u003e \u003cp\u003e2.6 Conclusions and Outlook 32\u003c\/p\u003e \u003cp\u003eReferences 33\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Theoretical Hydrogen‐Bonding Analysis for Assessment of Physical Stability of Pharmaceutical Solid Forms 37\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eYuriy A. Abramov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 37\u003c\/p\u003e \u003cp\u003e3.2 Experimental Scales of H‐Bonding Basicity and Acidity 39\u003c\/p\u003e \u003cp\u003e3.2.1 In Solution Phase 39\u003c\/p\u003e \u003cp\u003e3.2.2 In Solid‐State Phase 40\u003c\/p\u003e \u003cp\u003e3.3 Theoretical Study of H‐Bonding Strength in Solution and in Solid State 40\u003c\/p\u003e \u003cp\u003e3.3.1 Supermolecular Approach 41\u003c\/p\u003e \u003cp\u003e3.3.2 Descriptor‐Based Approaches 41\u003c\/p\u003e \u003cp\u003e3.3.3 Solid‐State H‐bonding Strength 42\u003c\/p\u003e \u003cp\u003e3.4 Application to Solid Form Selection 47\u003c\/p\u003e \u003cp\u003e3.4.1 Examples of Theoretical H‐Bonding Analysis to Support Solid Form Selection 48\u003c\/p\u003e \u003cp\u003e3.4.2 Consideration of Limitations of Hydrogen‐Bonding Propensity Approach 50\u003c\/p\u003e \u003cp\u003e3.5 Conclusion 52\u003c\/p\u003e \u003cp\u003eAcknowledgment 53\u003c\/p\u003e \u003cp\u003eReferences 53\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Improving Force Field Parameters for Small‐Molecule Conformation Generation 57\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDmitry Lupyan, Yuriy A. Abramov, and Woody Sherman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 57\u003c\/p\u003e \u003cp\u003e4.2 Methods 62\u003c\/p\u003e \u003cp\u003e4.3 Results and Discussion 66\u003c\/p\u003e \u003cp\u003e4.3.1 Close S⋯O Interactions 66\u003c\/p\u003e \u003cp\u003e4.3.2 Halogen X⋯O Interactions 75\u003c\/p\u003e \u003cp\u003e4.3.3 Generalization of the Approach to Other Interactions 77\u003c\/p\u003e \u003cp\u003e4.3.4 An Improved OPLS Force Field (OPLS2) 80\u003c\/p\u003e \u003cp\u003e4.4 Conclusion 81\u003c\/p\u003e \u003cp\u003eReferences 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Advances in Crystal Structure Prediction and Applications to Pharmaceutical Materials 87\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGraeme M. Day\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 87\u003c\/p\u003e \u003cp\u003e5.1.1 Motivation 88\u003c\/p\u003e \u003cp\u003e5.2 Crystal Structure Prediction Methodologies 89\u003c\/p\u003e \u003cp\u003e5.2.1 Molecular Geometry 89\u003c\/p\u003e \u003cp\u003e5.2.2 Crystal Structure Searching 99\u003c\/p\u003e \u003cp\u003e5.2.3 Structure Ranking 102\u003c\/p\u003e \u003cp\u003e5.3 Applications of Crystal Structure Prediction 105\u003c\/p\u003e \u003cp\u003e5.3.1 Crystal Structure Determination 106\u003c\/p\u003e \u003cp\u003e5.3.2 Solid Form Screening 108\u003c\/p\u003e \u003cp\u003e5.4 Summary 110\u003c\/p\u003e \u003cp\u003eReferences 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Integrating Computational Materials Science Tools in Form and Formulation Design 117\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJoseph F. Krzyzaniak, Paul A. Meenan, Cheryl L. Doherty, Klimentina Pencheva, Suman Luthra, and Aurora Cruz‐Cabeza\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 117\u003c\/p\u003e \u003cp\u003e6.2 From Molecule to Crystal Structure 119\u003c\/p\u003e \u003cp\u003e6.2.1 Single Crystal Structure 120\u003c\/p\u003e \u003cp\u003e6.2.2 Structural Analysis 120\u003c\/p\u003e \u003cp\u003e6.2.3 Molecular Packing and HB Geometry Analyses 122\u003c\/p\u003e \u003cp\u003e6.2.4 Full Interaction Maps 123\u003c\/p\u003e \u003cp\u003e6.2.5 Crystal Structure Prediction 124\u003c\/p\u003e \u003cp\u003e6.3 From Crystals to Particles 131\u003c\/p\u003e \u003cp\u003e6.4 From Particles to Dosage Forms 134\u003c\/p\u003e \u003cp\u003e6.4.1 Structural Investigation of Crystal Surfaces and Structure Dehydration 137\u003c\/p\u003e \u003cp\u003e6.4.2 Structural Investigations of Crystal Surfaces and Chemical Stability 139\u003c\/p\u003e \u003cp\u003e6.5 Conclusion 141\u003c\/p\u003e \u003cp\u003eAcknowledgments 142\u003c\/p\u003e \u003cp\u003eReferences 142\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Current Computational Approaches at Astrazeneca for Solid‐State and Property Predictions 145\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSten O. Nilsson Lill, Staffan Schantz, Viktor Broo, and Anders Broo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 145\u003c\/p\u003e \u003cp\u003e7.2 Polymorphism 146\u003c\/p\u003e \u003cp\u003e7.3 Conformer Search 157\u003c\/p\u003e \u003cp\u003e7.4 Molecular Perturbations to Achieve Solubility for GPR119 Ligands 158\u003c\/p\u003e \u003cp\u003e7.5 Solid‐State Nuclear Magnetic Resonance and Azd8329 Case Study 163\u003c\/p\u003e \u003cp\u003e7.6 CCDC Tools 168\u003c\/p\u003e \u003cp\u003e7.7 Tautomerism 169\u003c\/p\u003e \u003cp\u003e7.8 Conclusions 170\u003c\/p\u003e \u003cp\u003eAcknowledgments 170\u003c\/p\u003e \u003cp\u003eReferences 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Synthonic Engineering: From Molecular and Crystallographic Structure to the Rational Design of Pharmaceutical Solid Dosage Forms 175\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eKevin J. Roberts, Robert B. Hammond, Vasuki Ramachandran, and Robert Docherty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 175\u003c\/p\u003e \u003cp\u003e8.2 The Crystal 177\u003c\/p\u003e \u003cp\u003e8.2.1 Crystallography 177\u003c\/p\u003e \u003cp\u003e8.2.2 Crystal Chemistry and Crystal Packing of Drug Molecules 179\u003c\/p\u003e \u003cp\u003e8.2.3 Deconstructing the Supra‐Molecular Interactions in Bulk – Intrinsic Synthons 181\u003c\/p\u003e \u003cp\u003e8.3 Morphology and Surface Structure 185\u003c\/p\u003e \u003cp\u003e8.3.1 Nucleation and the Crystal Growth Process 185\u003c\/p\u003e \u003cp\u003e8.3.2 Particle Morphology and Surface Structure 186\u003c\/p\u003e \u003cp\u003e8.3.3 Crystal Morphology Prediction 188\u003c\/p\u003e \u003cp\u003e8.3.4 Deconstructing the Supra‐Molecular Interactions at Surfaces – Extrinsic Synthons 190\u003c\/p\u003e \u003cp\u003e8.3.5 Grid Searching – Probing Inter‐molecular Interactions at Surfaces and Environments 190\u003c\/p\u003e \u003cp\u003e8.4 The Crystallisation Perspective 191\u003c\/p\u003e \u003cp\u003e8.4.1 Nucleation, Surface Energies and Directed Polymorphism 191\u003c\/p\u003e \u003cp\u003e8.4.2 The Impact of Solvent on Morphology 194\u003c\/p\u003e \u003cp\u003e8.4.3 The Impact of Impurities on Morphology 196\u003c\/p\u003e \u003cp\u003e8.5 The Drug Product Perspective 197\u003c\/p\u003e \u003cp\u003e8.5.1 Excipient Compatibility 197\u003c\/p\u003e \u003cp\u003e8.5.2 Inhaled Drug Delivery Design 199\u003c\/p\u003e \u003cp\u003e8.5.3 Mechanical Properties 201\u003c\/p\u003e \u003cp\u003e8.5.4 Dissolution 203\u003c\/p\u003e \u003cp\u003e8.6 Summary and Future Outlook: Synthonic Engineering Particle Passport and the Future of the Drug Product Design 205\u003c\/p\u003e \u003cp\u003eAcknowledgements 207\u003c\/p\u003e \u003cp\u003eReferences 207\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 New Developments in Prediction of Solid‐State Solubility and Cocrystallization Using COSMO‐RS Theory 211\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eChristoph Loschen and Andreas Klamt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 211\u003c\/p\u003e \u003cp\u003e9.2 COSMO‐RS 212\u003c\/p\u003e \u003cp\u003e9.3 Prediction of Drug Solubility Using COSMO‐RS 215\u003c\/p\u003e \u003cp\u003e9.4 Solubility Prediction with Multiple Reference Solvents 218\u003c\/p\u003e \u003cp\u003e9.5 Melting Point and Fusion Enthalpy QSPR Models 221\u003c\/p\u003e \u003cp\u003e9.6 Cocrystal Screening 225\u003c\/p\u003e \u003cp\u003e9.7 Solvate Formation 229\u003c\/p\u003e \u003cp\u003e9.8 Summary 231\u003c\/p\u003e \u003cp\u003eReferences 231\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Modeling and Prediction of Solid Solubility by Ge Models 235\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLarissa P. Cunico, Anjan K. Tula, Roberta Ceriani, and Rafiqul Gani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 235\u003c\/p\u003e \u003cp\u003e10.2 Framework 236\u003c\/p\u003e \u003cp\u003e10.2.1 Thermodynamic Basis 238\u003c\/p\u003e \u003cp\u003e10.2.2 The Necessary Property‐Related Information for Solid Solubility Prediction and the Developed Databases 238\u003c\/p\u003e \u003cp\u003e10.2.3 SLE Thermodynamic Consistency Tests 241\u003c\/p\u003e \u003cp\u003e10.2.4 SolventPro 252\u003c\/p\u003e \u003cp\u003e10.3 Conclusion 259\u003c\/p\u003e \u003cp\u003eReferences 260\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Molecular Simulation Methods to Compute Intrinsic Aqueous Solubility of Crystalline Drug‐Like Molecules 263\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDavid S. Palmer and Maxim V. Fedorov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 263\u003c\/p\u003e \u003cp\u003e11.2 Definitions of Solubility 264\u003c\/p\u003e \u003cp\u003e11.3 Solubility and Thermodynamics 264\u003c\/p\u003e \u003cp\u003e11.3.1 Solubility and Free Energy of Solution 264\u003c\/p\u003e \u003cp\u003e11.3.2 Computation of Solubility from the Thermodynamic Cycle of Solid to Supercooled Liquid to Aqueous Solution 265\u003c\/p\u003e \u003cp\u003e11.3.3 Computation of Solubility from the Thermodynamic Cycle of Solid to Gas Phase to Aqueous Solution 267\u003c\/p\u003e \u003cp\u003e11.4 Calculation of Δ\u003ci\u003eG\u003c\/i\u003e\u003csub\u003ehyd \u003c\/sub\u003e269\u003c\/p\u003e \u003cp\u003e11.4.1 Implicit Continuum Solvent Models 270\u003c\/p\u003e \u003cp\u003e11.4.2 Explicit Solvent Models: Atomistic Simulations 270\u003c\/p\u003e \u003cp\u003e11.4.3 Explicit Solvent Models: Molecular Theories of Liquids 271\u003c\/p\u003e \u003cp\u003e11.5 Calculation of Δ\u003ci\u003eG\u003c\/i\u003e\u003csub\u003esub\u003c\/sub\u003e 275\u003c\/p\u003e \u003cp\u003e11.5.1 Crystal Polymorphism 275\u003c\/p\u003e \u003cp\u003e11.5.2 Crystal Structure Prediction 275\u003c\/p\u003e \u003cp\u003e11.5.3 Calculation of Δ\u003ci\u003eG\u003c\/i\u003e\u003csub\u003esub\u003c\/sub\u003e 276\u003c\/p\u003e \u003cp\u003e11.5.4 Calculation of Δ\u003ci\u003eH\u003c\/i\u003e\u003csub\u003esub\u003c\/sub\u003e 276\u003c\/p\u003e \u003cp\u003e11.5.5 Calculation of Δ\u003ci\u003eS\u003c\/i\u003e\u003csub\u003esub\u003c\/sub\u003e 277\u003c\/p\u003e \u003cp\u003e11.5.6 Other Methods to Compute Δ\u003ci\u003eG\u003c\/i\u003e\u003csub\u003esub\u003c\/sub\u003e 278\u003c\/p\u003e \u003cp\u003e11.6 Experimental Data 279\u003c\/p\u003e \u003cp\u003e11.7 Conclusion and Future Outlook 280\u003c\/p\u003e \u003cp\u003eAcknowledgments 280\u003c\/p\u003e \u003cp\u003eReferences 280\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Calculation of NMR Tensors: Application to Small‐Molecule Pharmaceutical Solids 287\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLuis Mafra, Sergio Santos, Mariana Sardo, and Heather Frericks Schmidt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 SSNMR Spectroscopy: A Short Introduction 287\u003c\/p\u003e \u003cp\u003e12.2 The Chemical Shielding Tensors: Fundamentals 288\u003c\/p\u003e \u003cp\u003e12.3 Computational Approaches to the Calculation of Chemical Shift Tensors in Solids 290\u003c\/p\u003e \u003cp\u003e12.3.1 Cluster Approach 290\u003c\/p\u003e \u003cp\u003e12.3.2 Periodic Approach 291\u003c\/p\u003e \u003cp\u003e12.3.3 Pitfalls and Practical Considerations 292\u003c\/p\u003e \u003cp\u003e12.4 NICS 294\u003c\/p\u003e \u003cp\u003e12.5 Case Studies Combining Experimental and Computational NMR Methods 294\u003c\/p\u003e \u003cp\u003e12.5.1 NMR Assignment of Polymorphs Aided by Computing NMR Parameters 295\u003c\/p\u003e \u003cp\u003e12.5.2 Calculated vs Experimental Chemical Shift Tensors Using Different NMR Methods 302\u003c\/p\u003e \u003cp\u003e12.5.3 Studying Crystal Packing Interactions 312\u003c\/p\u003e \u003cp\u003e12.5.4 Employing Chemical Shifts for Crystal Structure Elucidation\/Determination 315\u003c\/p\u003e \u003cp\u003e12.6 Summary 325\u003c\/p\u003e \u003cp\u003eReferences 326\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Molecular Dynamics Simulations of Amorphous Systems 331\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBradley D. Anderson and Tian‐Xiang Xiang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 331\u003c\/p\u003e \u003cp\u003e13.2 MD Simulation Methodology 332\u003c\/p\u003e \u003cp\u003e13.3 Polymer Properties—MD Simulation Versus Experiment 334\u003c\/p\u003e \u003cp\u003e13.3.1 Glass Transition Temperature (\u003ci\u003eT\u003c\/i\u003e\u003csub\u003eg\u003c\/sub\u003e) 334\u003c\/p\u003e \u003cp\u003e13.3.2 Amorphous Structure and Dynamics 337\u003c\/p\u003e \u003cp\u003e13.4 Hydrogen Bonding Patterns, Water Uptake, and Distribution in Amorphous Solids 342\u003c\/p\u003e \u003cp\u003e13.4.1 Poly(D,L)lactide 343\u003c\/p\u003e \u003cp\u003e13.4.2 Polyvinylpyrrolidone 345\u003c\/p\u003e \u003cp\u003e13.4.3 Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) 347\u003c\/p\u003e \u003cp\u003e13.4.4 Amorphous Indomethacin 350\u003c\/p\u003e \u003cp\u003e13.5 Amorphous Drug–Polymer Blends 354\u003c\/p\u003e \u003cp\u003e13.5.1 Molecular Interactions Probed by MD Simulation 354\u003c\/p\u003e \u003cp\u003e13.5.2 Solubility and Miscibility Prediction 357\u003c\/p\u003e \u003cp\u003e13.5.3 Molecular Mobility and Small‐Molecule Diffusion in Amorphous Dispersions 361\u003c\/p\u003e \u003cp\u003e13.5.4 Plasticization by Water Clusters 365\u003c\/p\u003e \u003cp\u003e13.6 Summary 367\u003c\/p\u003e \u003cp\u003eReferences 368\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Numerical Simulations of Unit Operations in Pharmaceutical Solid Dose Manufacturing 375\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEkneet Kaur Sahni, Shivangi Naik, and Bodhisattwa Chaudhuri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 375\u003c\/p\u003e \u003cp\u003e14.2 Numerical Method 376\u003c\/p\u003e \u003cp\u003e14.2.1 Contact Drying in an Agitated Filter Dryer 376\u003c\/p\u003e \u003cp\u003e14.2.2 Coating in a Conventional Pan Coater 378\u003c\/p\u003e \u003cp\u003e14.2.3 Modeling of milling in a Wiley Mill 379\u003c\/p\u003e \u003cp\u003e14.3 Experimental Method for Milling 380\u003c\/p\u003e \u003cp\u003e14.4 Results and Discussion 380\u003c\/p\u003e \u003cp\u003e14.4.1 Simulation of Contact Drying 380\u003c\/p\u003e \u003cp\u003e14.4.2 Simulation of Tablet Coating 384\u003c\/p\u003e \u003cp\u003e14.4.3 Simulation of Size Fragmentation (Milling) 387\u003c\/p\u003e \u003cp\u003e14.5 Summary and Conclusions 391\u003c\/p\u003e \u003cp\u003eReferences 392\u003c\/p\u003e \u003cp\u003eIndex 395\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49406908236119,"sku":"9781118700747","price":117.85,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118700747.jpg?v=1730497521","url":"https:\/\/bookcurl.com\/products\/computational-pharmaceutical-solid-state-chemistry-9781118700747","provider":"Book Curl","version":"1.0","type":"link"}